GT
ALNY icon

Greenleaf Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Greenleaf Trust’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,733
Closed -$1.09M – 809
2025
Q4 		$1.09M Sell
2,733
-2
-0.1% -$885 0.01% 315
2025
Q3 		$1.25M Buy
2,735
+5
+0.2% +$2.04K 0.01% 275
2025
Q2 		$890K Sell
2,730
-20
-0.7% -$5.53K 0.01% 344
2025
Q1 		$743K Buy
2,750
+28
+1% +$7.2K 0.01% 397
2024
Q4 		$641K Buy
2,722
+4
+0.1% +$1.05K 0.01% 446
2024
Q3 		$748K Sell
2,718
-2
-0.1% -$521 0.01% 414
2024
Q2 		$661K Sell
2,720
-143
-5% -$22.6K 0.01% 402
2024
Q1 		$428K Sell
2,863
-75
-3% -$12.5K ﹤0.01% 516
2023
Q4 		$562K Buy
2,938
+405
+16% +$69K 0.01% 423
2023
Q3 		$449K Sell
2,533
-90
-3% -$17.2K 0.01% 466
2023
Q2 		$498K Sell
2,623
-137
-5% -$27.2K 0.01% 452
2023
Q1 		$553K Buy
2,760
+61
+2% +$12.8K 0.01% 420
2022
Q4 		$641K Buy
2,699
+24
+0.9% +$5.12K 0.01% 370
2022
Q3 		$535K Buy
2,675
+118
+5% +$22.5K 0.01% 379
2022
Q2 		$373K Buy
2,557
+181
+8% +$25.7K 0.01% 487
2022
Q1 		$388K Sell
2,376
-811
-25% -$124K ﹤0.01% 495
2021
Q4 		$540K Hold
3,187
– – 0.01% 399
2021
Q3 		$602K Hold
3,187
– – 0.01% 344
2021
Q2 		$540K Buy
3,187
+40
+1% +$5.86K 0.01% 374
2021
Q1 		$444K Buy
3,147
+29
+0.9% +$4.36K 0.01% 412
2020
Q4 		$405K Sell
3,118
-13
-0.4% -$1.74K 0.01% 385
2020
Q3 		$456K Buy
3,131
+31
+1% +$4.41K 0.01% 305
2020
Q2 		$459K Hold
3,100
– – 0.01% 294
2020
Q1 		$337K Hold
3,100
– – 0.01% 310
2019
Q4 		$357K Buy
+3,100
New +$309K 0.01% 368

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Greenleaf Trust's ALNY Position: Q1 2026 in Review

Greenleaf Trust sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 2,733 shares — an estimated $1.09M sold.

Greenleaf Trust first reported a position in ALNY in Q4 2019 and held it in 25 quarters. The position peaked at $1.25M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Greenleaf Trust reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Greenleaf Trust sold 2,733 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.09M.
  • Greenleaf Trust first reported a position in Alnylam Pharmaceuticals in Q4 2019 and held it in 25 quarters.
  • Greenleaf Trust's Alnylam Pharmaceuticals position peaked at $1.25M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Greenleaf Trust's 13F filing for Q1 2026, filed 27 Apr 2026.